As clinical trials represent a substantial portion of R&D costs, the adoption of electronic data capture (EDC) over the last 15 years has contributed to these efficiencies. However, forward-thinking life sciences companies increasingly recognize that replacing paper with EDC is not an end in itself. Rather, EDC is the entry point for deeper and broader technology enablement that not only reduces trial cost, but brings treatments to market faster and reduces regulatory and business risk. These benefits can be achieved by enabling not just data capture, but the entire clinical trial process with smarter technology, moving from initial concept to regulatory approval and beyond. Therefore an integrated clinical development technology platform is becoming a strategic imperative for life science leaders.